Enhanced EGR1 activity promotes the growth of prostate cancer cells in an androgen-depleted environment

Journal of Cellular Biochemistry

Volumn 97, Issue 6, 2006, Pages 1292-1299

  Yang, Shan Zhong ^a,b   Eltoum, Isam A ^a   Abdulkadir, Sarki A ^a,c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgen independence; Androgen receptor; EGR1

Indexed keywords

ANDROGEN; EARLY GROWTH RESPONSE FACTOR 1; PROTEIN NAB2; REPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANDROGENS; ANIMALS; CELL NUCLEUS; CYPROTERONE ACETATE; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 33645654867     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.20736     Document Type: Article

References (21)

1. Abdulkadir SA, Carbone JM, Naughton CK, Humphrey PA, Catalona WJ, Milbrandt J. 2001a. Frequent and early loss of the EGR1 co-repressor NAB2 in human prostate carcinoma. Hum Pathol 32:935-939.
2. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, Gordon JI, Humphrey PA, Milbrandt J. 2001b. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 7:101-107.
3. Adamson ED, Mercola D. 2002. Egr1 transcription factor: Multiple roles in prostate tumor cell growth and survival. Tumour Biol 23:93-102.
4. Bakin RE, Gioeli D, Sikes RA, Bissonette EA, Weber MJ. 2003. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63:1981-1989.
5. Baron V, De Gregorio G, Krones-Herzig A, Virolle T, Calogero A, Urcis R, Mercola D. 2003. Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo. Oncogene 22:4194-4204.
6. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. 2003. Myc confers androgen-independent prostate cancer cell growth. J Clin Invest 112:1724-1731.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33-39.
8. Craft N, Shostak Y, Carey M, Sawyers CL. 1999. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285.
9. Denmeade SR, Isaacs JT. 2002. A history of prostate cancer treatment. Nat Rev Cancer 2:389-396.
10. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ. 1998. Expression of early growth response genes in human prostate cancer. Cancer Res 58:2461-2468.
11. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. 1998. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 58:5718-5724.
12. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. 1998. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 152:1-9.
13. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. 2001. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555.
14. Mahler C, Denis LJ. 1995. Hormone refractory disease. Semin Surg Oncol 11:77-83.
15. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN. 2002. Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81:191-201.
16. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R. 1995. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55:4438-4445.
17. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. 2000. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 275:38524-38531.
18. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. 1995. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398.
19. Thigpen AE, Cala KM, Guileyardo JM, Molberg KH, McConnell JD, Russell DW. 1996. Increased expression of early growth response-1 messenger ribonucleic acid in prostatic adenocarcinoma. J Urol 155:975-981.
20. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. 2003. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem 278:11802-11810.
21. Yang S-Z, Abdulkadir SA. 2003. Early growth response gene 1 modulates androgen receptor signaling in prostate carcinoma cells. J Biol Chem 278:39906-39911.